Tyzeka is a new oral antiviral for chronic hepatitis B

December 2006

Tyzeka is a new oral antiviral for chronic hepatitis B.

It's an alternative to using lamivudine (Epivir-HBV)...adefovir (Hepsera)...entecavir (Baraclude)...or interferons (Pegasys, etc).

Tyzeka (telbivudine) is well-tolerated like lamivudine...but it's more effective at suppressing the hepatitis B virus.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote